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Abstract
Background
Apixaban pharmacokinetic properties and some clinical reports suggest cessation 48 hours prior
to surgery is safe, but this has not been demonstrated in a naturalistic setting. We sought to measure
the residual apixaban exposure in patients who had apixaban held as part of standard of care perioperative management.
Methods
This was a prospective, observational study of patients in whom apixaban plasma concentration
and anti-Xa activity were measured while at steady state apixaban dosing and again immediately
prior to surgery. Clinical management of cessation and resumption of apixaban was at the
discretion of the treating physician.
Results
One hundred and eleven patients provided paired blood samples. Ninety four percent (104/111)
patients had measured apixaban concentrations of < 30 ng/mL. Only one patient had a value > 50
ng/mL. The median time between the self-reported last dose and pre-surgery blood sampling was
76 hours (range 32 – 158) for those who achieved concentrations < 30 ng/mL and 59 hours (range
49 – 86) for those > 30 ng/mL. Measured anti-Xa activity correlated well with apixaban exposure.
Clinically significant non-major bleeding was reported in one patient at 1-week post-surgery.
There was one venous thromboembolic event and one stroke in the peri-operative period.
Conclusion
In a naturalistic setting with a heterogeneous patient population, apixaban discontinuation for at
least 48 hours before a procedure resulted in a clinically insignificant degree of anticoagulation
prior to a surgical procedure. (NCT02935751)

Introduction
Apixaban is a direct oral anticoagulant (DOAC) approved for multiple indications. The need to
interrupt anticoagulation in the perioperative period is common. Approaches for the
discontinuation of DOACs are based upon the pharmacokinetic parameters of the drug in the
context of individual patient and procedural characteristics. The US apixaban product insert
specifies the last dose be held at least 24 hour before a low bleeding risk procedure and at least 48
hours prior to elective surgery or invasive procedures with a moderate or higher risk bleeding.(1)
This is based upon a population half-life of ~12 hours, only modest decreases in drug clearance
with hepatic or renal dysfunction, and linearity of pharmacokinetics across clinically used doses.
However, population pharmacokinetic methods have noted moderate between-patient variation
based upon known parameters such as age, size, and renal function, with unexplained covariates
accounting for ~30% of variation.(2) The additive effects of multiple patient characteristics may
impact apixaban clearance. Treating physicians may not be aware of all clinical factors that could
impact apixaban clearance. In addition, the clearance of apixaban declines after orthopedic surgery
by ~25%, which returns to baseline by post op day 4.(3) All of these factors highlight the potential
that in actual use, expected apixaban exposures may diverge from model predicted values. The
effectiveness of a peri-operative apixaban cessation approach in the setting of actual practice with
a heterogonous patient population was studied by Douketis in the PAUSE trial.(4) We
hypothesized that discontinuation of apixaban for at least 48 hours prior to surgical procedures in
a naturalistic observational setting would result in a clinically insignificant residual anticoagulation
as defined by apixaban plasma concentration <30 ng/mL.

Methods
This was a single site, prospective, observational study of patients receiving standard of care
perioperative management of apixaban anticoagulation (NCT02935751). The study population
was patients who were already receiving treatment with apixaban for non-valvular atrial
fibrillation or venous thromboembolism and who required an elective major surgical or invasive
procedure. All patients had a plasma apixaban and anti-Xa level drawn at steady state at the preadmission clinical visit and on the morning of surgery. The steady state concentration collection
was taken at the pre-admission visit. The time of collection relative to last dose of apixaban was
not fixed. Apixaban was stopped and restarted at the discretion of the treating physician, and there
was no protocol-specified or suggested interval for cessation. Institutional guidance suggested
cessation 48 hours prior to a surgical procedure. Adverse events and bleeding events were collected
to 30 days post procedure. Major bleeding was defined as fatal or in a critical organ, non- surgical
bleeding with a 2 g/dL decrease in hemoglobin or requiring transfusion of 2 units or more of blood,
surgical site bleeding that required surgical intervention or resulted in hemarthrosis within 30 days
of cessation of therapy. Arterial thromboembolic events, venous thromboembolism and death by
any cause were recorded if they occurred within 30 days of the last dose of apixaban. (Figure 1)
The Thomas Jefferson University Institutional Review Board approved the study, and all patients
were provided written informed consent.

Consecutive patients were assessed for study participation eligibility in the pre-admission testing
center. Inclusion criteria included adults greater than 18 years of age; on long term anticoagulation
with apixaban (5 mg or 2.5 mg twice daily) for treatment of non-valvular atrial fibrillation or
venous thromboembolism; scheduled for elective surgery or invasive procedure which required
anticoagulation interruption; and able to adhere to apixaban interruption protocol at the time of

enrollment. Patients were excluded if they had more than one procedure planned within 30 days;
creatinine clearance less than 30 mL/min; cognitive impairment or major psychiatric illness;
previous study participation or participation in another clinical trial. Patients with a creatinine
clearance < 30 mL/min were excluded at the time of this study base on our hospital’s guidelines
for the use of direct oral anticoagulants with creatinine clearance below this value at the time the
protocol was written. VTE prophylaxis is not routinely provided post-operatively pending
therapeutic DOAC re-initiation. A log of doses taken by the patient for the 7 days prior to surgery
was recorded. Before the procedure, patients were categorized as having a high or low bleeding
risk procedure according to a pre-specified classification listed in Supplemental Table 1. Patients
were followed daily during their hospitalization to assess resumption of apixaban and document
hemorrhagic or thrombotic events. Patients received phone contact at day 7 and 30 post discharge
to assess bleeding, thrombotic events or hospital readmission.

Statistical methods
The primary outcome of the ADIOS study was the estimation of the proportion of patients who
achieved a plasma apixaban concentration of <30 ng/mL following at least 48 hours of
discontinuation prior to surgery or invasive procedure. This threshold is based upon International
Society for Thrombosis and Hemostasis recommendations for reversal,(5) expert opinion as
clinically important,(6-8) and represents a value below that seen after 3-4 half-lives based upon
published pharmacokinetic parameters in patient populations.(2) The secondary outcome was the
incidence of postoperative arterial or venous thromboembolic events, major bleeding and clinically
significant non-major bleeding complications. Based on similar studies performed (9,10) in which
86% of patients had a plasma level at or below 30 ng/mL at least 48 hours after discontinuation,
we hypothesized that the proportion in the population was likely to be between 80% and 95% for

apixaban. One hundred thirty patients were chosen as having a reasonably narrow ClopperPearson(11) exact 95% confidence interval (CI) at the lowest anticipated observed proportion (CI
width of 0.15 if proportion is 0.80) and high confidence in the location of the population proportion
if nearly all or all patients reached the threshold of <30 ng/mL (CI widths of 0.08 and 0.03 for
proportions of 0.95 and 1.00, respectively). (Supplemental Table 2) All study variables were
summarized by means and standard deviations or, if substantially skewed, by medians with the
first and third quartiles using R version 4.0.2. Plots were generated using the R package ggplot2.
Pearson’s correlation coefficients were used to estimate correlation between the apixaban
concentration and anti-Xa apixaban activity. Two-sided significance was set at a=0.05.

Analytic procedure
Plasma concentrations of apixaban were determined by liquid chromatography-tandem mass
spectrometry using an AB Sciex API 3200MD.(12) Commercial calibrators (Hyphen Biomed)
were used, along with d4-rivaroxaban (Santa Cruz Biotechnology, Santa Cruz, CA) as an internal
standard. The calibration curve was linear over the range 0-600 ng/mL. Between-run precisions
were 8.4% (at 30 ng/mL) and 4.7% (at 200 ng/mL). The lower limit of quantitation (LLOQ) was
4 ng/mL. No analytical interferences or ion suppression effects have been observed in precedent
LC-MS/MS assays.(13) Anti-Xa was performed on ACL-TOP500 using Biophen Heparin LRT
and Biophen Apixaban calibrator from Aniara Diagnostica (West Chester, OH). Two level
controls (~72 and ~275 ng/mL, Biophen Apixaban control) were performed on each run.

Results:
Study Population
The enrollment period for the ADIOS trial lasted 18 months, from December 2016 through July

2018. Of the 130 patients enrolled in the trial, 111 paired blood samples were available for the
primary outcome of change in plasma apixaban concentration. (Figure 2) There were 19 patients
who were excluded due to missing variables, including missing apixaban concentrations at preadmission testing, day of surgery or both. The primary reason for a missed blood draw was last
minute cancellation of the scheduled surgery (6 patients), and 5 patients were missed because the
operating room schedule in the electronic medical record was inaccurate and patients were taken
for surgery earlier than anticipated. Two of the patients did not have a sample drawn because they
had difficult vein access, and the study coordinator could not get the sample after three attempts.
Patient apixaban dose was available for all 111 patients with paired blood samples. Patient
demographics and disposition are listed in Table 1. The proportion of patients achieving apixaban
concentrations of less than or equal to 30 ng/mL was 93.7%. (Figure 3)

The median time between the self-reported last dose and day of surgery blood sampling was 75.5
hours (32.4 – 157.8 hours) for those who achieved concentrations less than or equal to 30 ng/mL
and 59.3 hours (49.4 – 86.4 hours) for those greater than 30 ng/mL. Figures 4 and 5 display the
proportion of patients achieving target apixaban concentrations based on duration of apixaban
discontinuation and dose of apixaban, respectively. All seven patients who did not achieve target
plasma apixaban levels were on a maintenance dose of 5 mg twice daily. Pre-admission and preoperative concentrations of apixaban, and anti-Xa, and clinical characteristics of patients who did
and did not achieve target plasma apixaban levels are presented in Table 2.

Pharmacokinetic endpoint data was available for 111 of the 130 total patient population. A total
of eleven patients were lost to follow up with nine and two patients at one week and 4 week followups, respectively. Clinically significant non-major bleeding was reported in one patient at 1-week

post-surgery follow-up. There were two reported venous thromboembolic events during the study
and follow-up periods. Of these two, one had restart of apixaban at 50 hours and another at 158
hours post surgery. There were 10 major adverse cardiac events, 2 strokes and 5 arrhythmias. One
patient reported both stroke and arrhythmia during the initial hospitalization. Clinical endpoint
data is summarized in Table 3. A Welch two sample t-test was used to compare the binary
distribution between patients that had events to those that did not have events revealed that there
was no significant correlation between these events and mean plasma apixaban levels with a mean
difference of 0.25 ng/mL (95% CI: -14.6, 15.1, p = 0.97) between both groups.

Discussion:
A high proportion (100%) of patients achieved target apixaban concentrations (<30 ng/mL)
following at least 48-hours of discontinuation prior to surgery, and a greater proportion of patients
(>90%) achieved target apixaban levels after discontinuation for >60 hours. Patients who did not
achieve target plasma apixaban levels tended to be older and have poorer creatinine clearance,
with a mean (+ standard deviation) age of 71.4 (+ 10.7) years and median (range) creatinine
clearance of 44 (13 – 97) mL/min. The median concentration observed for these patients at the
pre-admission blood sampling was 330 (171 – 573) ng/mL. As home dosing the morning of
collection at steady state will have varied, these concentrations are considered random and do not
necessarily represent maximal (Cmax) or average steady state concentration for any one
individual. For comparison, predicted Cmax for patients receiving 5 mg BID for stroke prevention
in non-valvular atrial fibrillation is 171 ng/mL (95% CI 91, 321).(2) Our results suggest that the
recommended 48-hour discontinuation period is adequate for most individuals to achieve adequate
resolution of anticoagulation. The effect of these patient-specific factors was almost entirely absent

at 60 hours, suggesting that a discontinuation period longer than 3 days will not reduce
anticoagulation associated bleeding events in the peri-operative period. All 7 of the patients who
did not achieve the target plasma apixaban level of < 30 ng/mL were on a daily dose of 5 mg twice
daily, though none were taking concomitant inhibitors of CYP450 enzymes or p-glycoprotein.
Dose is a primary driver of systemic exposure. Dose, in addition to patient characteristics,
concomitant medications, and perceived bleeding risk, will play a role in a physician’s assessment
of individualizing the appropriate discontinuation time.

Anti-Xa levels were highly correlated with plasma apixaban, especially at higher prediscontinuation concentrations. Validity of the analytic method was demonstrated by significant
correlation (p < 0.001) between anti-Xa activity and plasma apixaban concentration measured on
the visit prior to discontinuation and on the day of surgery. (Supplemental Figure 1) This is
consistent with a known linearity between concentration and anti-Xa over a range of therapeutic
doses.(2) Further external validation of our methods was indicated by an apparent positive trend
between apixaban concentration and age, and a negative trend between apixaban concentration,
weight, and creatinine clearance measured at steady state (first blood draw). (Supplemental
Figures 2 and 3)

No significant safety issues were observed related to the discontinuation of apixaban. Of the 7
patients who had a day of surgery apixaban concentration of >30 ng/ml, only two experienced a
peri-operative adverse events neither of which were bleeding. Of the remaining 104 patients, the
rates of major adverse cardiac events, arterial thrombosis, recurrent venous thromboembolism, and
death were low, most of which were attributed to underlying disease rather than discontinuation

of apixaban. The primary endpoint of this observational study was pharmacokinetic and the study
was not powered to make inferences about the efficacy and safety of the apixaban discontinuation
approach recommended in the product insert. While the numbers were too small to perform a
robust statistical analysis, the small rates of cardiac and thromboembolic events suggest the safety
of the prescribed discontinuation period were reassuring. One of the major limitations of this trial
is that it was an observational study assessing provider-directed discontinuation rather than a
standardized protocol, which led to a wide range of pre-surgery discontinuation windows. Another
limitation was that the exact time of last dose for both visits was patient reported and subject to
recall bias and the variability associated with patient self-reporting in a naturalistic setting. This
lack of exact dose time and limited number of samples prevented the use of population
pharmacokinetic approaches that could have otherwise been used to identify covariates associated
with pharmacokinetic variation. Lastly, the reported cut off of 30 ng/mL was chosen as a
reasonable surrogate of a safe level for an invasive procedure. This has not been defined in large
studies with clinical endpoints. Despite the varied patient population, only one patient had an
apixaban concentration >50 ng/ml. For comparison, 50 ng/ml is the model predicted minimum
apixaban concentration for patients prescribed apixaban 2.5 mg BID for the prevention of
venothromboembolic events in hip or knee replacement surgery (95% CI 23,109).(3) While in the
PAUSE trial with a DOAC 48 hour prior to surgery discontinuation time, 90.5% of the apixaban
group achieved drug plasma level of less than 50 ng/ml. The major bleeding incidence was 2.96%
(95%CI, 0%-4.68%) in the apixaban group undergoing high bleeding risk surgery. (4) In patients
with serious bleeding, only a drug concentration > 50 ng/mL is likely sufficiently high to warrant
antidote administration, whereas in those requiring an urgent intervention associated with a high
risk of bleeding, antidote administration is advocated if the drug concentration exceeds 30 ng/mL.

(5,8) In the current study, even those with >30 ng/ml of apixaban had an order of magnitude
reduction in both apixaban and anti-Xa activity on the morning of surgery compared to steady state
concentration. The number of patients prescribed 2.5 mg was low. This is not an impact for those
prescribed this for prophylaxis, as pre-surgery concentrations will be expected to be lower than
those prescribed 5 mg. While formal pharmacokinetic modeling was not done on such a small set
of patients, even those taking the labeled dose reduction due to at least two of 1) age greater than
or equal to 80 years, 2) body weight less than or equal to 60 kg, or 3) serum creatinine greater than
or equal to 1.5 mg would be expected to have similar or lower apixaban pharmacokinetic exposure
than those prescribed 5 mg. In totality, the findings of this study suggest no role for anti-Xa assays
in the routine management of cessation of apixaban for elective surgical procedures. A strength of
this study is the generalizability of the results to patients assessed in clinical practice, as a high
proportion of screened patients were enrolled (83%). Another strength is the clinical applicability
of the apixaban regimen management we assessed, as most patients adhered to a physician directed
perioperative apixaban therapy interruption (95%) and resumption (93%) management protocol.

Conclusion
A large proportion of patients (93.7%; 95% CI: 88-97%) achieved plasma apixaban concentrations
of <30 ng/mL following at least 48 hours of discontinuation. A greater proportion (>90%) of
patients achieved below 30 ng/mL when apixaban was discontinued for >60 hours. The clinical
evidence here supports current pharmacokinetic discontinuation strategies based on patient factors
and apixaban half-life.
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Table 1: Baseline patient characteristics enrolled into the study
Age – years (SD)
Sex (Female)
BMI (kg/m2)
Race
White
Black or African American
Other
Unknown
Apixaban Indication
Reduction of risk of stroke/TIA or systemic embolism in non-valvular
atrial fibrillation (n=80)
2.5 mg
5 mg
Unknown
Prevention of recurrent venous thromboembolism (n=32)

N=130
68.6 + 11.6
52%
30 [21 – 52]
80.6%
15.4%
3.1%
0.8%
59%
8.8%
79.8%
11.4%
25%

2.5 mg
5 mg
Unknown

Multiple indications* (n=12)

18.8%
65.6%
15.6%

9%
2.5 mg
5 mg
Unknown

Unknown indication (n=6)

16.7%
66.7%
16.7%
5%

2.5 mg
5 mg
Unknown

0%
66.7%
33.3%

*12 patients were taking apixaban for multiple indications: 7 for reduction of risk of stroke in non-valvular atrial fibrillation and
prevention of recurrent venous thromboembolism; 1 for reduction of risk of stroke and prevention of recurrent transient ischemic
event secondary to atrial fibrillation; 2 for reduction of risk of stroke and prevention of recurrent stroke secondary atrial fibrillation;
1 for prevention of recurrent venous thromboembolism and prevention of recurrent stroke secondary to atrial fibrillation; and 1 for
reduction of risk of stroke in atrial fibrillation and prevention of recurrent venous thromboembolism and for prevention of recurrent
stroke secondary to atrial fibrillation

Table 2: Comparison of patient characteristics stratified by observed apixaban
concentration on the day of surgery
< 30 ng/mL (n=104)
68.7 + 11.9

> 30 ng/mL (n=7)
71.4 + 10.7

Sex (Female)
BMI (kg/m2)
Race

49%
30 [21 – 52)

50%
28 [25 – 38]

White
Black or African American
Other
Unknown
CHA2D2-VASc Score
Apixaban Dose
2.5 mg twice-daily
5 mg twice-daily
Pre-admission
Apixaban (ng/mL)
Anti-FXa (IU/mL)
Pre-surgery
Apixaban (ng/mL)
Anti-FXa (IU/mL)
Procedure Bleeding Risk
Standard
High
Median time following apixaban
cessation to day of surgery blood
draw (hours)
Median time of apixaban
resumption following the day of
surgery (hours)
Creatinine clearance (mL/min)
Concomitant medications
Diltiazem
Adenosine diphosphate inhibitor
Nonsteroidal anti-inflammatory
Aspirin

78.8%
16.3%
3.8%
1.0%
3.5 + 1.7

100%
0%
0%
0%
3.6 + 1.5

14.4%
85.6%

0%
100%

168.0 [13.0 – 485.0]
184.1 [0 – 418.3]

330.0 [171.0 – 573.0]
408.4 [184.0 – 544.4]

0.0 [0.0 – 30.0]
8.8 [8.8 – 29.4]

38.0 [31.0 – 66.0]
42.9 [42.9 – 80.5]

51%
49%
75.5 [32.4 – 157.8]

25%
75%
59.3 [49.4 – 86.4]

60.6 [6.8 – 471.2]

60.6 [21.8 – 152.3]

84 [4 – 188]

44 [13 – 97]

12.5%
4.8%
11.5%
18.3%

25%
0%
0%
37.5%

Age – years (SD)

Table 3. Peri-procedural and follow-up complications
Peri-procedural
complications
n/N (%)
All
18/111 (16.2%)
Any Major Adverse Cardiac
Event
5 (4.5%)
Stroke
1 (0.9%)
Arrhythmia
3 (2.7%)
Other
1 (0.9%)
Non-major Bleed
1 (0.9%)
Thromboembolic Event
1 (0.9%)
Infection
3 (2.7%)
Other
8 (7.2%)

1 Week Follow up

30 day Follow up

n/N (%)

n/N (%)

7/111 (6.3%)

9/111 (8.1%)

1 (0.9%)
0 (0%)
1 (0.9%)
0 (0%)
1 (0.9%)
1 (0.9%)
0 (0%)
4 (3.6%)

4/ (3.6%)
0 (0%)
1 (0.9%)
3 (2.7%)
1 (0.9%)
0 (0%)
1 (0.9%)
3 (2.7%)

Figures
Figure 1: Study design. Timing of cessation of apixaban prior to surgery was at the discretion of
the treating physician.

Figure 2: Study subject disposition

Figure 3: Proportion of patients grouped by apixaban concentrations > 30 ng/mL and with those
achieving < 30 ng/mL, with interquartile ranges.

Figure 4. Proportion of patients who had apixaban concentrations > 30 ng/mL according to time
since last dose.

Figure 5. Apixaban concentration following discontinuation on the day of surgery grouped by
dose

Supplemental Figure 1. Correlation between plasma apixaban concentration and apixaban antiXa activity

Supplemental Figure 2. Correlation between log plasma apixaban concentration and patient age, sex, weight and bleeding risk on the
initial visit prior to surgery. Sex and risk are bounded by interquartile ranges.

Supplemental Figure 3. Correlation between log plasma apixaban concentration and patient age, time after discontinuation, sex,
bleeding risk, weight, and creatinine clearance on the day of surgery. Sex and risk are bounded by interquartile ranges.

Supplemental Table 1. Surgical Procedures and Bleeding Risk

High risk for bleeding
1. Major cardiac surgery
2. Neurosurgery
3. Large hernia repair
4. Major cancer surgery
5. Major urologic surgery (prostate/bladder resection)
6. Major vascular surgery
7. Any other major operation with duration >45 minutes
8. Endoscopic large polyp resection
9. Esophageal variceal treatment, biliary sphincterectomy pneumatic dilatation
10. CT-guided fine-needle aspiration; kidney biopsy
11. Pacemaker/ICD insertion
12. Major dental procedure (multiple extractions)
Standard risk for bleeding
1. Major orthopedic surgery (joint replacement or laminectomy)
2. Coronary angiography /PCI/electrophysiologic testing
3. Indwelling catheter for neuraxial anesthesia
4. Cholecystectomy, appendectomy (open or laparoscopic)
5. Abdominal hernia repair
6. Abdominal hysterectomy
7. GI endoscopy ±biopsy, enteroscopy, biliary/pancreatic stent w/o sphincterotomy

Supplemental Table S2. Clopper-Pearson exact 95% confidence of plausible observed sample
proportions of those meeting the apixaban plasma level <30 ng/dL threshold after apixaban
discontinuation 48 hours prior to major surgery or invasive procedures.

Observed proportion plasma
apixaban <30 ng/mL

95% Confidence
Interval

Interval Width

0.80

(0.72, 0.87)

0.15

0.85

(0.78, 0.91)

0.13

0.90

(0.84, 0.95)

0.11

0.95

(0.90, 0.98)

0.08

1.00

(0.97, 1.00)

0.03

